| Symbol | OXBDF |
|---|---|
| Name | OXFORD BIOMEDICA PLC |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | OX4 6LT United Kingdom ENG Windrush Court, Transport Way |
| Telephone | +44 (0) 1865 783 00 |
| Fax | — |
| — | |
| Website | https://www.oxb.com/investors |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: LSE - London Stock Exchange |
| CIK | — |
| Description | Oxford Biomedica is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. Additional info from OTC: Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. |
No news found.